Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
102.78
+0.21 (0.20%)
May 20, 2024, 2:25 PM EDT - Market open
Novartis AG Employees
Novartis AG had 76,057 employees on December 31, 2023. The number of employees decreased by 25,646 or -25.22% compared to the previous year.
Employees
76,057
Change (1Y)
-25,646
Growth (1Y)
-25.22%
Revenue / Employee
$656,402
Profits / Employee
$200,442
Market Cap
201.15B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Merck & Co. | 72,000 |
Danaher | 63,000 |
AbbVie | 50,000 |
NVS News
- 4 days ago - Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash - GlobeNewsWire
- 5 days ago - Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA - GlobeNewsWire
- 13 days ago - Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer - Business Wire
- 18 days ago - Novartis to buy radiology specialist Mariana Oncology for $1 billion - Reuters
- 18 days ago - Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech - Market Watch
- 18 days ago - Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer - Business Wire
- 20 days ago - PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis - Business Wire
- 21 days ago - Morphosys says Novartis takeover progressing as planned for H1 2024 - Reuters